IP Library › Granted Patent US 12,576,068
Granted Patent B2
US 12,576,068 · App. 17/907,451 · Granted Mar 17, 2026

Compositions containing amino acids and methods of using such compositions for treating sarcopenia

Inventors: Claudia Roessle (Morges, CH); Denis Breuille (Lausanne, CH); Eugenia Migliavacca (Lausanne, CH); Jerome Feige (Crissier, CH)
Assignee: Societe des Produits Nestle S.A.
A61K31/4172A61K31/198A61K31/405A61K31/675A61P21/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,576,068
App. No.
17/907,451
Granted
Mar 17, 2026
Kind
B2
Abstract

A composition contains one or more aromatic amino acids and optionally vitamin B6. The composition may be an oral nutritional composition, for example a nutritional supplement, an oral nutritional supplement, a food product, a food for special medical purpose (FSMP). The composition can be in a form of a powder, a powdered stick, a capsule or a solution. The composition can be administered to an individual in need thereof orally or intravenously for preventing and/or treating sarcopenia, a loss of and/or improving skeletal muscle mass, lean muscle mass, skeletal muscle strength and/or skeletal muscle function.

Claims (15)

1 . A method for preventing and/or treating sarcopenia and/or for improving skeletal muscle mass, skeletal muscle lean mass, skeletal muscle strength and/or skeletal muscle function in an individual in need thereof, the method comprising administering to the individual a unit dosage form of a composition comprising (i) one or more aromatic amino acids (AAAs) in a therapeutically effective amount and (ii) vitamin B6 in an amount of 1.0-12.0 mg/300.0 Kcal of energy of the composition,

wherein the one or more aromatic amino acids are a combination of aromatic amino acids (AAAs) of Trp, Phe, Tyr and His; and daily dosages of total AAAs, the Trp, the Tyr, the Phe and the His are 3.0-20.0 g/day, 0.2-3.0 g/day, 1.5-8.8 g/day, 1.5-10.7 g/day and 0.9-5.6 g/day respectively.

2 . The method of claim 1 , wherein the one or more aromatic amino acids are selected from the group consisting of tryptophan (Trp), phenylalanine (Phe), tyrosine (Tyr), histidine (His) and combinations thereof.

3 . The method of claim 1 , wherein the unit further comprises EAAS and/or BCAAs selected from the group consisting of methionine (Met), lysine (Lys), valine (Val), leucine (Leu), Isoleucine (Ile), Threonine (Thr), and combinations thereof.

4 . The method of claim 1 , wherein the composition is in a form selected from the group consisting of an oral nutritional composition, a nutritional supplement, an oral nutritional supplement, a medical food, a food supplement, a food product, and a food for special medical purpose (FSMP).

5 . The method of claim 1 , wherein the composition is in a form selected from the group consisting of a solid powder, a powdered stick, a capsule and a solution.

6 . A method of preventing or treating sarcopenia in an individual in need thereof, the method comprising administering a composition containing (i) a therapeutically effective amount of one or more aromatic amino acids and (ii) vitamin B6 in an amount of 1.0-12.0 mg/300.0 Kcal of energy of the composition,

wherein the one or more aromatic amino acids are a combination of aromatic amino acids (AAAs) of Trp, Phe, Tyr and His; and daily dosages of total AAAs, the Trp, the Tyr, the Phe and the His are 3.0-20.0 g/day, 0.2-3.0 g/day, 1.5-8.8 g/day, 1.5-10.7 g/day and 0.9-5.6 g/day respectively.

7 . A method for restoring and/or correcting deficiencies of nutrients in a subject having sarcopenia or at risk thereof, the method comprising administering a composition containing (i) a therapeutically effective amount of one or more aromatic amino acids and (ii) vitamin B6 in an amount of 1.0-12.0 mg/300.0 Kcal of energy of the composition,

wherein the one or more aromatic amino acids are a combination of aromatic amino acids (AAAs) of Trp, Phe, Tyr and His; and daily dosages of total AAAs, the Trp, the Tyr, the Phe and the His are 3.0-20.0 g/day, 0.2-3.0 g/day, 1.5-8.8 g/day, 1.5-10.7 g/day and 0.9-5.6 g/day respectively.

8 . The method of claim 7 , wherein the one or more aromatic amino acids are selected from the group consisting of tryptophan (Trp), phenylalanine (Phe), tyrosine (Tyr), histidine (His) and combinations thereof.

9 . The method of claim 7 , wherein the composition further comprises EAAS and/or BCAAs selected from the group consisting of methionine (Met), lysine (Lys), valine (Val), leucine (Leu), Isoleucine (Ile), Threonine (Thr), and combinations thereof.

10 . The method of claim 7 , wherein the composition is administered in a daily dose comprising 1.0-25.0 mg vitamin B6 per day.

11 . The method of claim 1 , wherein the composition is administered in a daily dose comprising 1.0-25.0 mg vitamin B6 per day.

12 . The method of claim 6 , wherein the composition is administered in a daily dose comprising 1.0-25.0 mg vitamin B6 per day.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 11, 2026
From: ROESSLE, CLAUDIA; BREUILLE, DENIS; MIGLIAVACCA, EUGENIA; FEIGE, JEROME
To: SOCIETE DES PRODUITS NESTLE S.A.
Reel/Frame 073760/0148 →
Continuity (2)
Provisional Application 63003495 · Apr 1, 2020
Related Publication 20230131476A1 · Apr 27, 2023
References Cited (21)
US 20090181903A1 · Wolfe · 2009 [cited by examiner]
US 20200230093A1 · Giorgetti · 2020 [cited by examiner]
CN 103974631A · 2014 [cited by applicant]
CN 105120689A · 2015 [cited by applicant]
CN 105451578A · 2016 [cited by applicant]
CN 108024983A · 2018 [cited by applicant]
JP 2008510494A · 2008 [cited by applicant]
JP 2013515718A · 2013 [cited by applicant]
JP 2019058140A · 2019 [cited by applicant]
WO 2004026294A1 · 2004 [cited by applicant]
WO 2012141316A1 · 2012 [cited by applicant]
WO 2018091564A1 · 2018 [cited by applicant]
WO 2019035953 · 2019 [cited by applicant]
WO 2019090061 · 2019 [cited by applicant]
WO 2020018911A1 · 2020 [cited by applicant]
Suidasari et al. “Dietary vitamin B6 modulates the gene expression of myokines, Nrf2-related factors, myogenin and HSP60 in the skeletal muscle of rats” Experimental and Therapeutic Medicine, 2017, vol. 14, pp. 3239-324… [cited by applicant]
Olza et al. “A specific protein-enriched enteral formula decreases cortisolemia and improves plasma albumin and amino acid concentrations in elderly patients” Nutrition & Metabolism, 2010, vol. 7, No. 58, 8 pages. [cited by applicant]
Aytekin et al., “Selected B Vitamins and their Possible Link to the Aetiology of Age-related Sarcopenia: Relevance Of UK Dietary Recommendations”, Nutrition research reviews, vol. 31, 2018, pp. 204-224. [cited by applicant]
Japanese Office Action for Appl No. 2022-552639 dated Feb. 25, 2025, 6 pages. [cited by applicant]
Chinese Office Action for Appl No. 202180019809.7 dated Dec. 12, 2023. [cited by applicant]
Japanese Office Action for Appl No. 2022-552639 dated Nov. 18, 2025, 4 pages. [cited by applicant]